Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  C R Bard Inc    BCR

Delayed Quote. Delayed  - 09/30 06:43:24 pm
223.505 USD   -0.11%
09/22 C R BARD : LUTONIX® Global Real-World Registry 24-Month Outcomes Pre..
09/19 C R BARD : FDA Approves 6-Month Primary End Point for the Lutonix® B..
09/08 C R BARD : Bard to Present at Morgan Stanley Global Healthcare Confe..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

BARD(CR) : Bard Announces Agreement to Acquire Medivance, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/25/2011 | 10:15pm CEST

C. R. Bard, Inc. (NYSE: BCR) today announced that it has reached a definitive agreement to acquire Medivance, Inc. for a purchase price of approximately $250 million. The transaction will be structured as a merger subject to the satisfaction of customary conditions, including Hart-Scott-Rodino clearance. Upon completion of the merger, the Medivance organization will become part of Bard Medical division.

Medivance, located in Louisville, Colorado, is the market leader in the field of therapeutic hypothermia. In recent years, accurate manipulation of body temperature to targeted levels has emerged as an effective treatment option for a variety of critically ill patients. The American Heart Association, The American Stroke Association, The Brain Trauma Foundation and various international medical associations have issued therapeutic hypothermia guidelines as the clinical data supporting Targeted Temperature Management? has grown. Medivance's Arctic Sun® family of products provides clinicians with a powerful technology to effectively manage patient temperature in a non-invasive manner.

Timothy M. Ring, chairman and CEO, commented, "With their unique and proprietary technology, Medivance is the market leader in an emerging and growing space. This merger is a great strategic fit for Bard as Medivance's Targeted Temperature Management? product line is synergistic with our critical care sales call point, and their technology efficiently addresses a large unmet need in a market that is growing double digits. This acquisition represents an important building block for our critical care product offering."

Based on the anticipated completion of the merger in the fourth quarter of 2011, Bard expects the dilution impact to be immaterial to earnings per share in 2011.

C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current expectations, the accuracy of which is necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as "anticipate", "estimate", "expect", "project", "intend", "forecast", "plan", "believe", and other words of similar meaning in connection with any discussion of future operating or financial performance. Many factors may cause actual results to differ materially from anticipated results including product developments, sales efforts, income tax matters, the outcomes of contingencies such as legal proceedings, and other economic, business, competitive and regulatory factors. The company undertakes no obligation to update its forward-looking statements. Please refer to the Cautionary Statement Regarding Forward-Looking Information in our June 30, 2011 Form 10-Q for more detailed information about these and other factors that may cause actual results to differ materially from those expressed or implied.

C. R. Bard, Inc.
Investor Relations:
Todd W. Garner, 908-277-8065
Vice President, Investor Relations
or
Media Relations:
Scott T. Lowry, 908-277-8365
Vice President and Treasurer


© Business Wire 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on C R BARD INC
09/22 C R BARD : LUTONIX® Global Real-World Registry 24-Month Outcomes Presented at VI..
09/19 C R BARD : FDA Approves 6-Month Primary End Point for the Lutonix® Below-the-Kne..
09/08 C R BARD : Bard to Present at Morgan Stanley Global Healthcare Conference
09/06 C R BARD : Bard to Present at Morgan Stanley Global Healthcare Conference
07/27 C R BARD : BARD C R INC /NJ/ Management's Discussion and Analysis of Financial C..
07/26 C R BARD : tops Street 2Q forecasts
07/26 BARD C R INC /NJ/ : Results of Operations and Financial Condition, Financial Sta..
07/26 C R BARD : Bard Announces Second Quarter Results
07/14 C R BARD INC : ex-dividend day
07/08 Medtech's 2016 stock surge confronts second-quarter test
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
09/29DJMEDTRONIC : FDA Approves Medtronic's New Automated Insulin Pump -- Update
09/28DJMEDTRONIC : FDA Approves Medtronic's New Automated Insulin Pump
09/28DJMEDTRONIC : FDA Approves Medtronic's New Automated Insulin Pump
09/28DJMEDTRONIC : FDA Approves Medtronic's New Automated Insulin Pump
09/17DJJ&J to Buy Abbott Eye Business -- WSJ
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
09/26 BEST NEAR-TERM PRICE GAINS AHEAD FOR : Medical Supply Stocks
09/16 Healthcare ratings roundup - upgrades/downgrades
09/16 Healthcare ratings roundup - new coverage
09/15 BECTON, DICKINSON : Big Earnings Increases Should Bring Big Capital Allocation I..
08/22 PREMIER DIVIDEND GROWTH STOCKS : Is There Any Value? A Sector By Sector Summary ..
Advertisement
Financials ($)
Sales 2016 3 680 M
EBIT 2016 1 066 M
Net income 2016 679 M
Debt 2016 515 M
Yield 2016 0,44%
P/E ratio 2016 26,80
P/E ratio 2017 21,92
EV / Sales 2016 4,61x
EV / Sales 2017 4,44x
Capitalization 16 435 M
More Financials
Chart C R BARD INC
Duration : Period :
C R Bard Inc Technical Analysis Chart | BCR | US0673831097 | 4-Traders
Full-screen chart
Technical analysis trends C R BARD INC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Average target price 243 $
Spread / Average Target 8,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Tim M. Ring Chairman & Chief Executive Officer
John H. Weiland President, Chief Operating Officer & Director
Christopher S. Holland Chief Financial Officer & Senior Vice President
John A. DeFord Senior VP-Science, Technology & Clinical Affairs
Patricia G. Christian VP-Quality, Regulatory & Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
C R BARD INC18.11%16 435
MEDTRONIC PLC11.02%118 017
ZIMMER BIOMET HOLDINGS..24.61%25 570
BAXTER INTERNATIONAL I..22.99%25 519
SYSMEX CORP-3.71%15 506
TERUMO CORP6.60%14 853
More Results